Francois Brisebois
Stock Analyst at Oppenheimer
(2.27)
# 2,656
Out of 4,761 analysts
87
Total ratings
41.86%
Success rate
-1.47%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $0.57 | +605.47% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $48.72 | +47.78% | 7 | Jan 22, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $8.18 | +144.50% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $13.07 | +114.23% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $8.47 | +254.19% | 8 | Oct 31, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $79.54 | +104.93% | 4 | Oct 31, 2024 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Outperform | $56 → $59 | $34.89 | +69.10% | 5 | Oct 30, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $13.99 | +293.14% | 5 | Sep 3, 2024 | |
| KALA KALA BIO | Reiterates: Outperform | $15 | $6.84 | +119.30% | 2 | Aug 19, 2024 | |
| DMAC DiaMedica Therapeutics | Reiterates: Outperform | $6 | $6.61 | -9.23% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $3.22 | +241.61% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $16.75 | -16.42% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $15 | $2.69 | +457.62% | 4 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.98 | +528.14% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $31.84 | +104.15% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $6.72 | +48.81% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.81 | +517.28% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $9.33 | +1,529.15% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $18.61 | +93.44% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $2.83 | +41.34% | 3 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.55 | +10,807.11% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $5.34 | +101,023.60% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 | $0.47 | +953.74% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8.5 | $3.06 | +177.78% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $4.27 | +157.61% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $1.86 | +867.74% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $4.54 | +1,001.32% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $2.55 | +126,958.82% | 1 | Feb 4, 2020 |
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $0.57
Upside: +605.47%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $48.72
Upside: +47.78%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $8.18
Upside: +144.50%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $13.07
Upside: +114.23%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $8.47
Upside: +254.19%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $79.54
Upside: +104.93%
Harmony Biosciences Holdings
Oct 30, 2024
Reiterates: Outperform
Price Target: $56 → $59
Current: $34.89
Upside: +69.10%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $13.99
Upside: +293.14%
KALA BIO
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $6.84
Upside: +119.30%
DiaMedica Therapeutics
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $6.61
Upside: -9.23%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.22
Upside: +241.61%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $16.75
Upside: -16.42%
Jun 26, 2024
Maintains: Outperform
Price Target: $11 → $15
Current: $2.69
Upside: +457.62%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $3.98
Upside: +528.14%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $31.84
Upside: +104.15%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $6.72
Upside: +48.81%
Apr 1, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.81
Upside: +517.28%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $9.33
Upside: +1,529.15%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $18.61
Upside: +93.44%
Apr 4, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $2.83
Upside: +41.34%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.55
Upside: +10,807.11%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $5.34
Upside: +101,023.60%
Oct 3, 2022
Upgrades: Outperform
Price Target: $5
Current: $0.47
Upside: +953.74%
Sep 7, 2022
Initiates: Outperform
Price Target: $8.5
Current: $3.06
Upside: +177.78%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $4.27
Upside: +157.61%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $1.86
Upside: +867.74%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $4.54
Upside: +1,001.32%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $2.55
Upside: +126,958.82%